Acadian Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$3.53M Sell
1,557,036
-1,676,999
-52% -$3.81M 0.01% 673
2025
Q1
$2.05M Buy
3,234,035
+96,989
+3% +$61.6K 0.01% 748
2024
Q4
$3.23M Buy
3,137,046
+36,052
+1% +$37.1K 0.01% 643
2024
Q3
$3.66M Buy
3,100,994
+372,425
+14% +$439K 0.01% 576
2024
Q2
$3.32M Buy
2,728,569
+37,739
+1% +$46K 0.01% 616
2024
Q1
$5.86M Buy
2,690,830
+44,640
+2% +$97.3K 0.02% 434
2023
Q4
$4.1M Hold
2,646,190
0.02% 505
2023
Q3
$3.41M Sell
2,646,190
-7,386
-0.3% -$9.52K 0.01% 547
2023
Q2
$4.56M Hold
2,653,576
0.02% 486
2023
Q1
$4.01M Hold
2,653,576
0.02% 517
2022
Q4
$4.24M Hold
2,653,576
0.02% 490
2022
Q3
$3.85M Buy
2,653,576
+814,350
+44% +$1.18M 0.02% 476
2022
Q2
$3.37M Buy
1,839,226
+954,119
+108% +$1.75M 0.02% 510
2022
Q1
$2.36M Buy
885,107
+473,885
+115% +$1.26M 0.01% 631
2021
Q4
$1.78M Sell
411,222
-289,768
-41% -$1.25M 0.01% 687
2021
Q3
$3.57M Sell
700,990
-348,149
-33% -$1.77M 0.01% 533
2021
Q2
$6.64M Buy
1,049,139
+102,178
+11% +$647K 0.03% 396
2021
Q1
$7.32M Buy
946,961
+259,071
+38% +$2M 0.03% 385
2020
Q4
$4.51M Buy
687,890
+105,675
+18% +$692K 0.02% 524
2020
Q3
$3.87M Buy
582,215
+286,216
+97% +$1.9M 0.02% 499
2020
Q2
$2.47M Buy
295,999
+23,816
+9% +$198K 0.01% 680
2020
Q1
$2.09M Buy
272,183
+68,641
+34% +$526K 0.01% 593
2019
Q4
$1.69M Buy
203,542
+109,909
+117% +$914K 0.01% 737
2019
Q3
$691K Sell
93,633
-56,209
-38% -$415K ﹤0.01% 999
2019
Q2
$1.68M Buy
149,842
+29,568
+25% +$332K 0.01% 667
2019
Q1
$1.29M Buy
+120,274
New +$1.29M 0.01% 814
2018
Q3
Sell
-50,883
Closed -$1.16M 1678
2018
Q2
$1.16M Sell
50,883
-22,406
-31% -$512K 0.01% 694
2018
Q1
$2.09M Buy
+73,289
New +$2.09M 0.01% 580
2017
Q4
Sell
-1,608
Closed -$29K 1593
2017
Q3
$29K Sell
1,608
-2,524
-61% -$45.5K ﹤0.01% 1171
2017
Q2
$64K Buy
+4,132
New +$64K ﹤0.01% 1096